Paper Details

  1. Home
  2. Paper Details

Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer.

Author: HusinkaLakyn, KoernerPamela H, MillerRick T, TrombattWilliam

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study assessed the safety, cost, and utilization of CDK 4/6 inhibitors (palbociclib, abemaciclib, and ribociclib) for metastatic breast cancer. The study found that CDK 4/6 inhibitors are safe and well-tolerated, with over 60% of patients not experiencing adverse drug events. The study also found that patient co-pays were significantly lower than the average wholesale price of the medications. The study recommends that real-world safety data, out-of-pocket costs, and patient-specific comorbidities should be considered when developing a treatment plan that includes CDK 4/6 inhibitors.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The purpose of this study is to review CDK 4/6 inhibitors used to treat metastatic breast cancer for patient safety, cost and utilization. By evaluating patient outcomes and payer influence, this study will provide critical information to aid prescribers in therapeutic decisions. METHODS...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751387/

データ提供：米国国立医学図書館（NLM）

CDK 4/6 Inhibitors: A New Frontier in Breast Cancer Treatment

The quest for effective treatments for [breast cancer] continues, and [targeted therapy] is playing an increasingly significant role. This study focuses on the use of [CDK 4/6 inhibitors] in the treatment of [metastatic breast cancer], exploring their safety, cost, and utilization. The authors conducted a [retrospective cohort study] analyzing data from patients receiving palbociclib, abemaciclib, or ribociclib for treatment. The study assessed patient outcomes, payer influence, and therapy adherence.

Safety and Tolerability: A Promising Sign in Breast Cancer Treatment

The study demonstrated the safety and tolerability of CDK 4/6 inhibitors in patients with HR-positive/HER2-negative breast cancer. The authors noted that over 60% of the patients did not experience an adverse drug event during the study period. While ribociclib had the fewest reported side effects, abemaciclib patients reported the most.

Navigating the Landscape of Treatment Decisions: Balancing Benefits and Risks

The study highlights the importance of considering both the potential benefits and risks of CDK 4/6 inhibitors in the context of individual patient characteristics and comorbidities. It emphasizes the need for careful monitoring of patients and open communication between patients and their healthcare providers to ensure optimal outcomes. Imagine a desert oasis where patients with breast cancer can access effective and safe treatments, allowing them to embrace life with renewed hope and strength.

Dr. Camel's Conclusion

This study is like a camel caravan embarking on a journey to find new pathways for treating breast cancer. The use of CDK 4/6 inhibitors represents a promising new frontier in targeted therapy, offering hope to patients battling this challenging disease. The study's findings emphasize the importance of balancing benefits and risks, ensuring that patients can navigate this complex landscape with confidence and receive the best possible care.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-04-19
Further Info :

Pubmed ID

33414982

DOI: Digital Object Identifier

PMC7751387

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.